What the research found

A 40-week trial tracked 120 adults (average age ~60, mostly sedentary at baseline) taking tirzepatide. Half received the medication alone; the other half also completed a structured resistance training program—three supervised one-hour sessions weekly, progressing over five phases. Both groups achieved nearly identical fat loss (~17 kg average), and both showed cardiometabolic improvements like better blood pressure.

The divergence emerged in strength testing. The medication-only group lost 8.4% of bench-press strength and 9% of knee-extension strength. The training group gained 10.7% in bench press and 17.5% in knee extension. Notably, the resistance-training group still lost lean tissue despite becoming stronger—a reminder that strength and muscle mass are separate properties. Strength was a secondary outcome, not the trial's primary focus.

Why it matters for you

If you're using tirzepatide or similar GLP-1/GIP agonists and tracking body composition via DXA scans, this study highlights a critical blind spot: the scale and fat mass tell only part of the story. You may lose fat steadily while losing strength and function if you're not training. For most users—especially those over 50—that trade-off undermines the practical gains from weight loss. You lose weight but become less capable in daily tasks.

The flip side is equally important: adding resistance work is not optional cosmetics. It appears to be what actually preserves or builds strength despite drug-induced lean-tissue loss. If your protocol includes tirzepatide but not structured resistance training with progression, you're relying on medication to do what exercise does better. The training group attended 91% of sessions on average—adherence was high, but the program required real infrastructure (facility, equipment, qualified coaches).

Caveats

• Highly selected population: sedentary older adults; results may not generalise to younger, more active users or different demographics
• Structured intervention vs. real-world practice: the training program was supervised and progressive; typical gym use or home workouts differ substantially
• Secondary outcome: strength was measured as planned but wasn't the trial's primary question
• No "medication vs. exercise" comparison: both groups took tirzepatide, so we can't isolate drug effects from training effects alone
• Lean mass loss despite strength gain: the training group's ability to build strength while losing muscle raises questions about composition and quality that the study design doesn't fully resolve